重组人血小板生成素治疗白血病化疗后血小板减少症的疗效和安全性

Efficacy and safety of recombinant human thrombopoietin on leukothrombopenia

目的 探讨重组人血小板生成素（rhTPO）治疗白血病化疗后血小板减少症的临床效果.方法 收集2014年4月至2016年4月白血病化疗后血小板减少症患者80例,随机分为两组,每组40例.对照组给予重组人白介素-11（rhIL-11）皮下注射,观察组则给予rhTPO皮下注射.比较两组治疗效果.结果 治疗2周后,观察组最大血小板计数（PLT）高于对照组,观察组PLT〈50×109/L及恢复至（75-100）×109/L用时短于对照组,差异有统计学意义（P〈0.05）.观察组不良反应发生率为12.5%（5/40）,低于对照组60.0%（24/40）,差异有统计学意义（χ2=48.817,P〈0.05）.结论 rhTPO治疗白血病化疗后PLT减少症疗效好,安全性高.

Objective To investigate the efficacy of recombinant human thrombopoietin（rhTPO） on leukothrombopenia.Methods Eighty patients with leukothrombopenia were selected from April 2014 to April 2016,and were randomly divided into the two groups,with 40 cases in each group.The control group was treated by hypodermic injection of recombinant human interleukin-11（rhIL-11）,and the observation group was given rhTPO subcutaneous injection.The efficacy was compared between the two groups.Results After two weeks of treatment,the largest platelet count（PLT） of the observation group was higher than that of the control group,PLT〈50×109/L and restored to（75-100） ×109/L time were shorter than that of the control group,the differences were significant（P〈0.05）.The incidence rate of adverse reactions in observation group was 12.5%（5/40）,which was lower than 60.0%（24/40） of the control group,the difference was significant（χ2=48.817,P〈0.05）.Conclusions The treatment effect of PLT in patients with leukemia after chemotherapy with rhTPO is significant,and the safety is higher.